Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
Int J Med Sci
; 18(6): 1356-1362, 2021.
Article
in English
| MEDLINE | ID: covidwho-1089155
ABSTRACT
Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review, we described the evidence of the IL-6 response in patients with COVID-19, clarified the pathogenesis of the role of IL-6-mediated CRS in severe COVID-19, and highlighted the rationale for the use of anti-IL-6 agents and key information regarding the potential features of these IL-6 inhibitors in COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Interleukin-6
/
Cytokine Release Syndrome
/
COVID-19
Limits:
Humans
Language:
English
Journal:
Int J Med Sci
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Ijms.53564
Similar
MEDLINE
...
LILACS
LIS